Overview
The Critical Role of Managed Care Pharmacists in Optimizing Treatment of Iron Deficiency in Patients with Heart Failure. Held in conjunction with AMCP NEXUS 2023.
Symposium at AMCP Nexus
Click the "Register" button to register for this activity.
Register
Start your day with CPE! Iron deficiency (ID) is a common comorbidity in patients with heart failure (HF) that leads to worsening of HF symptoms and decreased quality of life. This symposium will review approaches to recognizing ID, the role of intravenous iron repletion, and strategies to overcome common barriers. The faculty panel will engage in a case-based discussion on avoiding suboptimal outcomes and driving systematic process change.
This educational activity is designed for hospital and managed care pharmacists.
Heart failure (HF) continues to be a global epidemic with high morbidity and mortality, considerable healthcare costs, and hospital admissions and readmissions. Iron deficiency (ID), irrespective of the presence of anemia, is a common comorbidity in patients with HF that can lead to worsening of HF symptoms and decreased quality of life. Yet, overall awareness of ID in HF is low. A diagnosis of ID in patients with HF can be challenging with new recommendations calling for monitoring of ID more frequently and more broadly, not just at the time of a HF diagnosis. ID in the HF setting is also undertreated despite guideline recommendations and accumulating data on the benefits of intravenous (IV) iron repletion. Administration of IV iron across providers and hospital and outpatient settings requires collaboration and coordination. Pharmacists can play a key role in identifying at-risk patients, mitigating barriers to use, improving treatment adherence, and outlining the benefits versus risks to support formulary management of IV iron formulations, reduce hospital readmissions, and improve patient outcomes.
Upon completion of this activity, learners will be able to:
- Interpret clinical data of intravenous iron repletion for the treatment of iron deficiency in HF patients
- Outline strategies to facilitate the use of IV iron for ID in HF patients based on the current evidence, guideline recommendations and patient reported outcomes
- Discuss the full clinical and economic impact of IV iron in patients with both chronic and acute HF beyond the effects on hospitalization and mortality
- Identify the role of the managed care pharmacist in the transitions of care for patients with ID and anemia in HF to ensure appropriate use and monitoring of parenteral iron
6:00: Registration
6:30: Welcome and Introductions
6:35: Recognizing ID in HF
6:55: Treatment of ID Across the HF Spectrum
7:20: Case-Based Discussion of Challenges and Solutions
7:50: Questions and Answers
8:00: Adjourn
6:30: Welcome and Introductions
6:35: Recognizing ID in HF
6:55: Treatment of ID Across the HF Spectrum
7:20: Case-Based Discussion of Challenges and Solutions
7:50: Questions and Answers
8:00: Adjourn
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from American Regent, Inc.
Stormi Gale, PharmD, BCCP, BCPS, FHFSA
Clinical Pharmacist
Heart and Vascular Institute
Novant Health
Huntersville, NC
Clinical Pharmacist
Heart and Vascular Institute
Novant Health
Huntersville, NC
B. Andrew Mardis, PharmD, BCCP, BCTXP, BCPS
Clinical Pharmacy Specialist, Advanced Heart Failure
Prisma Health–Midlands
Affiliate Clinical Assistant Professor
University of South Carolina College of Pharmacy
Columbia, SC
Muthiah Vaduganathan, MD, MPH
Cardiologist, Brigham and Women’s Hospital
Harvard Medical School
Boston, MA
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Stormi Gale, PharmD, BCCP, BCPS, FHFSA
No financial relationships to disclose
Muthiah Vaduganathan, MD, MPH
Sources of Funding for Research: American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health
Advisory Boards: American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health
Speakers' Bureau: American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health
Clinical Investigator: AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics
B. Andrew Mardis, PharmD, BCCP, BCTXP, BCPS
Consulting Agreements: Wolters-Kluwer
Speakers' Bureau: AstraZeneca, Boehringer-Ingelheim, Lilly
Advisory Board Member: Boehringer-Ingelheim, Lilly
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose
Guidelines require that learners in CME activities be made aware of all relevant financial relationships affecting the presentation of the faculty member. ACHL ensures that all faculty and staff involved in the planning, development, and implementation of ACHL activities disclose financial relationships held within 24 months and that relevant financial relationships are mitigated before a CME activity occurs. Complete information will be provided to learners prior to the start of the educational activity.
To receive credit, participants are required to participate in the live activity and complete the posttest and evaluation and submit on-site. CPE credit will be submitted to CPE Monitor® in early November. There is no fee to participate in the activity or to receive credit.
Partial credit may not be awarded for CPE credit; participation in the entire symposium is required to receive credit.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity has been approved for 1.50 contact hours.
ACPE Universal Activity Number: 0396-0000-23-031-L01-P
Activity Type: Application
CPE credit will be submitted to CPE Monitor® on the first business day of each month.
